Zai Lab Ltd ADR Repr 1 Shs ZLAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
-
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
-
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
-
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
-
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
-
Zai Lab, Amgen Team Up for Lung Cancer Clinical Trial
Trading Information
- Previous Close Price
- $26.34
- Day Range
- $25.41–26.52
- 52-Week Range
- $15.96–34.72
- Bid/Ask
- $25.12 / $27.00
- Shares Outstanding
- 112.27M
- Market Cap
- $2.86B
- Volume/Avg
- 1,330 / 935,302
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.29
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,784
- Website
- https://www.zailaboratory.com
Valuation
|
Metric
|
ZLAB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.72 |
Price/Sales | 6.29 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ZLAB
|
|---|---|
Quick Ratio | 1.61 |
Current Ratio | 2.13 |
Interest Coverage | −35.53 |
Quick Ratio
ZLAB
Profitability
|
Metric
|
ZLAB
|
|---|---|
Return on Assets (Normalized) | −13.93% |
Return on Equity (Normalized) | −22.33% |
Return on Invested Capital (Normalized) | −19.27% |
Return on Assets
ZLAB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|lJ!Hwk | LOCK|HMb?n | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>ry!f<^ | LOCK|D#$$% | $76B | |||
| Moderna Inc
MRNA
| LOCK|##mYNt | LOCK|Gxx | $75B | |||
| argenx SE ADR
ARGX
| LOCK|y<#t<@ | LOCK|by# | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%c<!s# | LOCK|j> | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|ZM!qkyC | LOCK|fQ#Jh | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Z>!!^jvC | LOCK|FDtf$ | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|tC%&>y? | LOCK|T< | $24B | |||
| Incyte Corp
INCY
| LOCK|GZL<&f | LOCK|^s | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Py>lW!K | LOCK|!f | $15B |
United States